Vitamin D, vitamin D receptor and tissue barriers

Tissue barriers are critical in the pathogenesis of human diseases, such as atopic dermatitis, inflammatory bowel diseases and various cancers. Preserving or restoring barrier functions of the epithelia cells is a therapeutic strategy to prevent and treat the illness. Mounting evidence indicates that vitamin D and the vitamin D receptor (VDR) play key roles in the pathogenesis of human diseases. In particular, we note an interesting link between vitamin D/VDR signaling and tissue barriers. In the current review, we summarize the recent progress on vitamin D and cell junction complexes. We focus on the functions of VDR and VDR-associated intracellular junction proteins, such as β-catenin and claudins. We also discuss the potential therapeutic functions of vitamin D in treating defective tissue barriers that involve skin, intestine, lung, kidney and other organs. However, the mechanisms for the vitamin D/VDR signaling in tissue barriers remain largely unknown. Further studies on vitamin D/VDR’s multiple functions in physiological models will suggest new therapeutic targets for prevention and treatment diseases with defective barrier functions.

[1]  Wei Li,et al.  Cytochrome P450scc-dependent metabolism of 7-dehydrocholesterol in placenta and epidermal keratinocytes. , 2012, The international journal of biochemistry & cell biology.

[2]  D. Agrawal,et al.  Vitamin D deficiency decreases the expression of VDR and prohibitin in the lungs of mice with allergic airway inflammation. , 2012, Experimental and molecular pathology.

[3]  Wei Li,et al.  In vivo evidence for a novel pathway of vitamin D3 metabolism initiated by P450scc and modified by CYP27B1 , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  Hong Zhang,et al.  Protective role of 1,25(OH)2vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute colitis in mice , 2012, BMC Gastroenterology.

[5]  L. Deftos,et al.  PTH/PTHrP and Vitamin D Control Antimicrobial Peptide Expression and Susceptibility to Bacterial Skin Infection , 2012, Science Translational Medicine.

[6]  A. Fitzpatrick,et al.  Vitamin D and asthma , 2012, Dermato-endocrinology.

[7]  C. Loddenkemper,et al.  Vitamin D receptor activation improves allergen-triggered eczema in mice. , 2012, The Journal of investigative dermatology.

[8]  J. Goff,et al.  Targeted delivery of vitamin D to the colon using β-glucuronides of vitamin D: therapeutic effects in a murine model of inflammatory bowel disease. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[9]  M. Haussler,et al.  Molecular Mechanisms of Vitamin D Action , 2012, Calcified Tissue International.

[10]  D. Bikle Vitamin D and the skin: Physiology and pathophysiology , 2012, Reviews in Endocrine and Metabolic Disorders.

[11]  M. Campbell,et al.  KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells. , 2011, Human molecular genetics.

[12]  B. Hammock,et al.  Vitamin D enhances corneal epithelial barrier function. , 2011, Investigative ophthalmology & visual science.

[13]  Shelley Gorman,et al.  Vitamin D deficiency causes deficits in lung function and alters lung structure. , 2011, American journal of respiratory and critical care medicine.

[14]  V. Tangpricha,et al.  Vitamin D and chronic lung disease: a review of molecular mechanisms and clinical studies. , 2011, Advances in nutrition.

[15]  I. Rahman,et al.  Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formation. , 2011, Biochemical and biophysical research communications.

[16]  Duane D. Miller,et al.  20-Hydroxyvitamin D2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells. , 2011, American journal of physiology. Cell physiology.

[17]  R. Wilkinson,et al.  High-dose vitamin D3 during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial , 2011, The Lancet.

[18]  M. Campbell,et al.  KDM 6 B / JMJD 3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells , 2011 .

[19]  Duane D. Miller,et al.  20-Hydroxyvitamin D 2 is a noncalcemic analog of vitamin D with potent antiproliferative and prodifferentiation activities in normal and malignant cells , 2011 .

[20]  Chang-zheng Wang,et al.  1,25-dihydroxyvitamin D₃ pretreatment enhances the efficacy of allergen immunotherapy in a mouse allergic asthma model. , 2010, Chinese medical journal.

[21]  Jun Sun Vitamin D and mucosal immune function , 2010, Current opinion in gastroenterology.

[22]  Yinglin Xia,et al.  Vitamin D receptor negatively regulates bacterial-stimulated NF-kappaB activity in intestine. , 2010, The American journal of pathology.

[23]  Ryan E. Forster,et al.  The nuclear vitamin D receptor controls the expression of genes encoding factors which feed the “Fountain of Youth” to mediate healthful aging , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[24]  A. Muñoz,et al.  The effects of 1,25-dihydroxyvitamin D3 on colon cancer cells depend on RhoA-ROCK-p38MAPK-MSK signaling , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[25]  Sneha S. Joshi,et al.  Mechanisms involved in vitamin D mediated intestinal calcium absorption and in non-classical actions of vitamin D , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  L. Adorini,et al.  Efficacy of a potent and safe vitamin D receptor agonist for the treatment of inflammatory bowel disease. , 2010, Immunology letters.

[27]  S. Milatz,et al.  Claudin-2, a component of the tight junction, forms a paracellular water channel , 2010, Journal of Cell Science.

[28]  Michael Karin,et al.  Inflammation and colon cancer. , 2010, Gastroenterology.

[29]  M. Ståhle,et al.  Topical treatment with the vitamin D analogue calcipotriol enhances the upregulation of the antimicrobial protein hCAP18/LL‐37 during wounding in human skin in vivo , 2010, Experimental dermatology.

[30]  T. Ruzicka,et al.  Control of cutaneous antimicrobial peptides by vitamin D3 , 2010, Archives of Dermatological Research.

[31]  H. DeLuca,et al.  Identification of a highly specific and versatile vitamin D receptor antibody. , 2010, Archives of biochemistry and biophysics.

[32]  F. Campbell,et al.  The Yin and Yang of vitamin D receptor (VDR) signaling in neoplastic progression: Operational networks and tissue-specific growth control , 2010, Biochemical pharmacology.

[33]  M. Furuse Molecular basis of the core structure of tight junctions. , 2010, Cold Spring Harbor perspectives in biology.

[34]  B. Coll,et al.  A new role for vitamin D receptor activation in chronic kidney disease. , 2009, American journal of physiology. Renal physiology.

[35]  Z. Tulassay,et al.  Comparison of the effects of 1,25 dihydroxyvitamin D and 25 hydroxyvitamin D on bone pathology and disease activity in Crohn's disease patients , 2009, Inflammatory bowel diseases.

[36]  C. Carlberg,et al.  The Nuclear Receptor Superfamily , 2016, Methods in Molecular Biology.

[37]  A. Proal,et al.  Vitamin D Metabolites as Clinical Markers in Autoimmune and Chronic Disease , 2009, Annals of the New York Academy of Sciences.

[38]  G. P. Studzinski,et al.  Vitamin D and differentiation in cancer , 2009, Critical reviews in clinical laboratory sciences.

[39]  T. Ruzicka,et al.  Vitamin D Analogs Differentially Control Antimicrobial Peptide/“Alarmin”Expression in Psoriasis , 2009, PloS one.

[40]  S. Zeissig,et al.  Epithelial Tight Junctions in Intestinal Inflammation , 2009, Annals of the New York Academy of Sciences.

[41]  J. Schulzke,et al.  Tight Junctions , 2009, Annals of the New York Academy of Sciences.

[42]  C. V. Van Itallie,et al.  Claudin‐2‐dependent Changes in Noncharged Solute Flux Are Mediated by the Extracellular Domains and Require Attachment to the PDZ‐scaffold , 2009, Annals of the New York Academy of Sciences.

[43]  稲富 周一郎 Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca[2+] absorption between enterocytes , 2009 .

[44]  D. Rodríguez‐Puyol,et al.  Oral active vitamin D is associated with improved survival in hemodialysis patients. , 2008, Kidney international.

[45]  R. Gallo,et al.  Administration of oral vitamin D induces cathelicidin production in atopic individuals. , 2008, The Journal of allergy and clinical immunology.

[46]  A. Muñoz,et al.  Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. , 2008, Anticancer research.

[47]  R. Heaney Vitamin D in health and disease. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[48]  D. Rubin,et al.  Claudin-1 and claudin-2 expression is elevated in inflammatory bowel disease and may contribute to early neoplastic transformation , 2008, Laboratory Investigation.

[49]  L. Adorini,et al.  Control of autoimmune diseases by the vitamin D endocrine system , 2008, Nature Clinical Practice Rheumatology.

[50]  M. Osanai,et al.  Tight junction proteins claudin-2 and -12 are critical for vitamin D-dependent Ca2+ absorption between enterocytes. , 2008, Molecular biology of the cell.

[51]  C. Mathieu,et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. , 2008, Endocrine reviews.

[52]  M. Zasloff,et al.  Diagnosis and treatment of vitamin D deficiency , 2008, Expert opinion on pharmacotherapy.

[53]  G. Ning,et al.  Novel role of the vitamin D receptor in maintaining the integrity of the intestinal mucosal barrier. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[54]  E. Severson,et al.  JAM-A regulates permeability and inflammation in the intestine in vivo , 2007, The Journal of experimental medicine.

[55]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[56]  M. Katoh,et al.  WNT Signaling Pathway and Stem Cell Signaling Network , 2007, Clinical Cancer Research.

[57]  L. Sage Fountain of youth , 2007 .

[58]  A. Muñoz,et al.  The inhibition of Wnt/β-catenin signalling by 1α,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells , 2007 .

[59]  U Wahnschaffe,et al.  Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease , 2006, Gut.

[60]  J. M. González-Sancho,et al.  The inhibition of Wnt/beta-catenin signalling by 1alpha,25-dihydroxyvitamin D3 is abrogated by Snail1 in human colon cancer cells. , 2007, Endocrine-related cancer.

[61]  C. V. Van Itallie,et al.  Claudin profiling in the mouse during postnatal intestinal development and along the gastrointestinal tract reveals complex expression patterns. , 2006, Gene expression patterns : GEP.

[62]  M. Demay Mechanism of Vitamin D Receptor Action , 2006, Annals of the New York Academy of Sciences.

[63]  J. Welsh,et al.  The Molecular Basis of Vitamin D Receptor and β-Catenin Crossregulation , 2006 .

[64]  J. Welsh,et al.  The molecular basis of vitamin D receptor and beta-catenin crossregulation. , 2006, Molecular cell.

[65]  G. Camussi,et al.  Treatment with 1, 25-Dihydroxyvitamin D3 Preserves Glomerular Slit Diaphragm-Associated Protein Expression in Experimental Glomerulonephritis , 2005, International journal of immunopathology and pharmacology.

[66]  H. Koeffler,et al.  Human cathelicidin antimicrobial peptide (CAMP) gene is a direct target of the vitamin D receptor and is strongly up‐regulated in myeloid cells by 1,25‐dihydroxyvitamin D3 , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[67]  M. Hernán,et al.  Activated injectable vitamin D and hemodialysis survival: a historical cohort study. , 2005, Journal of the American Society of Nephrology : JASN.

[68]  A. Ivanov,et al.  The epithelium in inflammatory bowel disease: potential role of endocytosis of junctional proteins in barrier disruption. , 2004, Novartis Foundation symposium.

[69]  Timothy R Church,et al.  Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. , 2003, Journal of the National Cancer Institute.

[70]  A. G. de Herreros,et al.  Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β-catenin signaling , 2001, The Journal of cell biology.

[71]  I. Arnott,et al.  Abnormal Intestinal Permeability Predicts Relapse in Inactive Crohn Disease , 2000, Scandinavian journal of gastroenterology.

[72]  M. Haussler,et al.  The Nuclear Vitamin D Receptor: Biological and Molecular Regulatory Properties Revealed , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  H. Lochs,et al.  Intestinal permeability and the prediction of relapse in Crohri's disease , 1993, The Lancet.

[74]  D. Hollander,et al.  Crohn's disease--a permeability disorder of the tight junction? , 1988, Gut.